Measuring Medication Safety.qxd Measuring medication safety with smart IV systems www.
author: gbon
Measuring Medication Safety.qxd page 62
author: gbon
Measuring Medication Safety.qxd page 61
author: gbon
Measuring Medication Safety.qxd page 14
author: gbon
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
Genentech: Investor Relations - Financials - 1997 First Quarter Report In a current Phase III clinical trial, Genentech is testing whether the effectiveness of Activase in the treatment of acute ischemic stroke will extend out to five hours after the onset of symptoms, beyond the three-hour treatment window for which it is currently marketed.Activase ...
Genentech: About Us - Corporate Overview - Corporate Growth Strategy Home Contact Us Site Index Search [ About Us -- Corporate Overview -- Corporate Growth Strategy -- 5X5 Goals ] Corporate Overview Home History Awards & Recognition Corporate Growth Strategy 5x5 Goals--- Horizon 2010 Compliance Programs 5X5 Goals Our 5X5 goals began in 1999 and continue in place through 2005.
Genentech: Investor Relations - Financials - 2000 Second Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2000 Second Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2000 Third Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2000 Third Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2001 Third Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2001 Third Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Products - Product Information - TNKase Home Contact Us Site Index Search [ Products -- TNKase ] Products Home ONCOLOGY Avastin Herceptin Rituxan Tarceva IMMUNOLOGY Raptiva Xolair VASCULAR MEDICINE Activase Cathflo Activase TNKase Full Prescribing Information TNKase Fact Sheet The Future of Heart Attack Treatment Heart Attack Fact Sheet TNKase Mechanism of Action SPECIALTY BIOTHERAPEUTICS Nutropin Nutropin AQ...
Genentech: Products - Product Information - Cathflo Activase Home Contact Us Site Index Search [ Products -- Cathflo Activase ] Products Home ONCOLOGY Avastin Herceptin Rituxan Tarceva IMMUNOLOGY Raptiva Xolair VASCULAR MEDICINE Activase Cathflo Activase Full Prescribing Information Cathflo Activase Fact Sheet Proposed Mechanism of Action Central Venous Access Devices CVAD FAQ TNKase SPECIALTY BIOTHERAPEUTICS Nutropin...
SY161, a cost-effective treatment of acute myocardial infarction - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
http://www.gene.com/gene/products/information/pdf/tnkase-mediaalert.pdf Media Alert BI Media Contact: Ute Schmidt +49- 61- 32- 779- 7296 Genentech Media Contact: Marites Cristobal 650- 225- 8226 Dawn Kalmar 650- 225- 5873 BOEHRINGER INGELHEIM AND GENENTECH ANNOUNCE EARLY TERMINATION OF A PHASE IIIb/ IV STUDY OF TNKASE/ METALYSE USED PRIOR TO ANGIOPLASTY IN PATIENTS WITH SEVERE HEART ATTACKS Ingelheim, Germany and South San Francisco, Calif.
author: Genentech, Inc.
http://www.gene.com/gene/products/information/pdf/tnkase-mediaalert.pdf page 2
author: Genentech, Inc.
untitled Total Product S ales $3,749 $3,749 Ritux an Av astin Growth Hormone Throm bolytic Xol air Pulmozyme RAPTIVA Other Herceptin $1 ,7 1 1 555 354 200 189 1 7 8 56 Tarcev a 1 3 10 483 0 500 1000 1500 2000 2500 3000 3500 4000 2002 $2,164 2003 $2,621 2004 14 Marketed Products, 1 (Unaudited) 2004 Total Product Sales (in millions) 0 1000 2000 0 200 400 600 0 100 200 300 400 500 0 100 200 300...
22723txt We let the science lead usActivase ® (Alteplase, recombinant), TNKaseª (Tenecteplase) and Cathfloª Activase ® (...
author: amag4-pickle
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf We own or have rights to various copyrights, trademarks and trade names used in our business including the following: Activase ® (alteplase, recombinant) tissue- plasminogen activator; Avastin ’ (bevacizumab) anti- VEGF antibody; Cathflo ® Activase ® (alteplase for catheter clearance); Herceptin ® (trastuzumab) anti- HER2 antibody; Lucentis ’...
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf page 5
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/financialhighlights.pdf genentech 8 % CHANGE FROM PRECEDING YEAR YEARS ENDED DECEMBER 31, 2003 2002 2001 2003/ 2002 2002/ 2001 Total operating revenues $3, 300.2 $2, 583.7 $2, 044.1 28% 26% Product sales 2, 621.4 2, 163.6 1, 742.9 21 24 Cost of sales (COS) 480.1 441.6 354.5 9 25 Research and development (R& D) expenses 722.0 623.5 526.2 16 18 R& D expenses as a % of operating revenues 22% 24% 26% N N...
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/financialhighlights.pdf page 2
Therapeutic Biological Approvals 3294 West Bayshore Road Palo Alto, CA 94303 License 1267 2/10/2000 Activase Alteplase - - Genentech, Inc 1 DNA Way South San Francisco, CA 94080-4990 License 1048 6/18/1996 Activase Alteplase Labeling Change: Addition of information regarding orolingual angioedema to the Precautions and Adverse Reactions sections, and bolding a statement in the Dosage and...
CBER - Alteplase (Cathflo Activase), Genentech Incorporated Garnick: Your request to supplement your biologics license application for Alteplase, to provide for a 2 mg vial strength and a new indication for the restoration of function to central venous access devices (as assessed by the ability to withdraw blood) has been approved
CBER - Alteplase (Activase), Genentech, Incorporated FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Product Approval Information - Licensing Action DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration 1401 Rockville Pike Rockville, MD 20852-1448 May 15, 2002 Our STN: BL 103172/5009 Robert L
